Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III double-blind randomized trial of QY201 in adolescents with moderate-to-severe atopic dermatitis
CTR20262132Phase 3Active
- Sponsor
- Origin Biosciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing QY201 10 mg with Placebo (2 arms). Primary endpoints: EASI-75 response rate at Week 16 and IGA-TS response rate at Week 16. Started Jun 2026; status: active.
02
Drugs
qy201
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20262132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262132.